Koers Benitec Biopharma Limited Deutsche Boerse AG
Aandelen
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 145 mln. 97,7 mln. 89,54 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -34 mln. -22,9 mln. -20,99 mln. | Nettowinst (verlies) 2025 * | -42 mln. -28,29 mln. -25,93 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-2,06
x | K/w-verhouding 2025 * |
-5,55
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 90,72% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Jerel Banks
CEO | Chief Executive Officer | 49 | 01-10-16 |
Peter Roelvink
CTO | Chief Tech/Sci/R&D Officer | - | 01-03-15 |
Megan Boston
CMP | Compliance Officer | 52 | 01-08-16 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
J. Buchi
BRD | Director/Board Member | 69 | 01-04-13 |
Edward Smith
BRD | Director/Board Member | 53 | 14-04-20 |
Peter Francis
BRD | Director/Board Member | 68 | 01-02-06 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+25,83% | 47,96 mld. | |
+46,00% | 41,47 mld. | |
+0,69% | 42,45 mld. | |
+30,52% | 31,6 mld. | |
+22,30% | 28,63 mld. | |
-6,35% | 28,03 mld. | |
+49,25% | 14,56 mld. | |
+49,18% | 14,14 mld. | |
+3,45% | 12,58 mld. |